ReviewAustralian prescriber2025
Potentially inappropriate medicines for older people: consensus-based lists.
Review in Australian prescriber, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Comparison of existing polypharmacy measures to a measure incorporating all modes of administration: an observational study using routinely collected data.International journal of clinical pharmacy · 2026Observational
- Tools to support medication management in people with multimorbidity and polypharmacy.Australian prescriber · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Older people, especially with multimorbidity and polypharmacy, are at higher risk of adverse medication outcomes compared with younger adults. To guide safer prescribing for older people, several lists of 'potentially inappropriate medicines' (PIMs lists) have been developed. Prominent PIMs lists include the Beers Criteria (USA) and the Screening Tool of Older People's Prescriptions (STOPP) (Europe). A new Australian PIMs list was published in 2024. PIMs are medicines for which there is evidence or consensus expert opinion that the potential risks usually outweigh the clinical benefits in a specific patient cohort. The Australian PIMs list outlines medicines that should be avoided in all older people, and medicines that should be avoided in certain clinical contexts. It also provides guidance on potentially safer alternatives to the listed medicines. Importantly, medicines included in PIMs lists are not always inappropriate. There may be clinical scenarios where a PIM is appropriate for an individual patient (hence the term
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.